{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:28Z","timestamp":1794047428663,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Acute myeloid leukemia (AML) with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) has a very poor prognosis. Determinants of clinical outcomes and optimal treatment remain uncertain. We retrospectively reviewed 108 cases of AML with inv(3)\/t(3;3) and evaluated clinicopathological characteristics and clinical outcomes: 53 newly diagnosed (ND) AML and 55 relapsed\/refractory (R\/R) AML. Median age was 55 years. White blood cell (WBC) count \u226520x109\/L and platelet count \u2265140x109\/L was observed in 25% and 32% of ND patients, respectively. Anomalies involving chromosome 7 were identified in 56% of patients. The most frequently mutated genes were SF3B1, PTPN11, NRAS, KRAS and ASXL1. In ND patients, the composite complete remission (CRc) rate was 46% overall; 46% with high-intensity treatments and 47% with lowintensity treatments. The 30-day mortality was 14% and 0%, with high- and low-intensity treatment, respectively. In R\/R patients, the CRc rate was 14%. Venetoclax based-regimens were associated with a CRc rate of 33%. The 3-year overall survival (OS) was 8.8% and 7.1% in ND and R\/R patients, respectively. The 3-year cumulative incidence of relapse was 81.7% overall. Older age, high WBC, high peripheral blast count, secondary AML and KRAS, ASXL1, DNMT3A mutations were associated with worse OS in univariable analyses. The 5-year OS rates were 44% and 6% with or without hematopoietic stem cell transplantation in CR1, respectively. AML with inv(3)\/t(3;3) is associated with low CR rates, very high risk of relapse and dismal long-term survival. Intensive chemotherapy and hy pomethylating agents provide similar rates of remission and patients achieving CR benefit from hematopoietic stem cell transplantation in first CR.<\/jats:p>","DOI":"10.3324\/haematol.2022.282030","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:25:54Z","timestamp":1679545554000},"page":"2331-2342","source":"Crossref","is-referenced-by-count":12,"title":["Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)"],"prefix":"10.3324","volume":"108","author":[{"given":"Guillaume","family":"Richard-Carpentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Dinardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"51213","doi-asserted-by":"crossref","unstructured":"Dohner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"51214","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International consensus classification of myeloid neoplasms and ncute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"51215","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"51216","doi-asserted-by":"crossref","unstructured":"Grimwade D, Hills RK, Moorman AV. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-365.","DOI":"10.1182\/blood-2009-11-254441"},{"key":"51217","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10):579-590.","DOI":"10.1038\/nrclinonc.2012.150"},{"key":"51218","doi-asserted-by":"crossref","unstructured":"Groschel S, Sanders MA, Hoogenboezem R. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014; 157(2):369-381.","DOI":"10.1016\/j.cell.2014.02.019"},{"key":"51219","doi-asserted-by":"crossref","unstructured":"Yamazaki H, Suzuki M, Otsuki A. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014; 25(4):415-427.","DOI":"10.1016\/j.ccr.2014.02.008"},{"key":"51220","doi-asserted-by":"crossref","unstructured":"Goyama S, Yamamoto G, Shimabe M. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008; 3(2):207-220.","DOI":"10.1016\/j.stem.2008.06.002"},{"key":"51221","doi-asserted-by":"crossref","unstructured":"Zhang Y, Stehling-Sun S, Lezon-Geyda K. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood. 2011; 118(14):3853-3861.","DOI":"10.1182\/blood-2011-02-334680"},{"key":"51222","doi-asserted-by":"crossref","unstructured":"Ayoub E, Wilson MP, McGrath KE. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nat Commun. 2018; 9(1):4239.","DOI":"10.1038\/s41467-018-06208-y"},{"key":"51223","doi-asserted-by":"crossref","unstructured":"Katayama S, Suzuki M, Yamaoka A. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis. Blood. 2017; 130(7):908-919.","DOI":"10.1182\/blood-2016-12-756767"},{"key":"51224","doi-asserted-by":"crossref","unstructured":"Sun J, Konoplev SN, Wang X. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol. 2011; 24(3):384-389.","DOI":"10.1038\/modpathol.2010.210"},{"key":"51225","doi-asserted-by":"crossref","unstructured":"Lugthart S, Groschel S, Beverloo HB. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010; 28(24):3890-3898.","DOI":"10.1200\/JCO.2010.29.2771"},{"key":"51226","doi-asserted-by":"crossref","unstructured":"Rogers HJ, Vardiman JW, Anastasi J. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014; 99(5):821-829.","DOI":"10.3324\/haematol.2013.096420"},{"key":"51227","doi-asserted-by":"crossref","unstructured":"Lavallee VP, Gendron P, Lemieux S, D'Angelo G, Hebert J, Sauvageau G. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 2015; 125(1):140-143.","DOI":"10.1182\/blood-2014-07-591529"},{"key":"51228","doi-asserted-by":"crossref","unstructured":"Groschel S, Sanders MA, Hoogenboezem R. Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways. Blood. 2015; 125(1):133-139.","DOI":"10.1182\/blood-2014-07-591461"},{"key":"51229","doi-asserted-by":"crossref","unstructured":"Breems DA, Van Putten WL, De Greef GE. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008; 26(29):4791-4797.","DOI":"10.1200\/JCO.2008.16.0259"},{"key":"51230","doi-asserted-by":"crossref","unstructured":"Kleinbaum DG, Klein M. Survival Analysis: a Self-Learning Text, Third Edition. 2012.","DOI":"10.1007\/978-1-4419-6646-9"},{"key":"51231","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021; 39(25):2768-2778.","DOI":"10.1200\/JCO.20.03736"},{"key":"51232","doi-asserted-by":"crossref","unstructured":"Walter RB, Othus M, Borthakur G. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011; 29(33):4417-4423.","DOI":"10.1200\/JCO.2011.35.7525"},{"key":"51233","doi-asserted-by":"crossref","unstructured":"Lugthart S, Figueroa ME, Bindels E. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2011; 117(1):234-241.","DOI":"10.1182\/blood-2010-04-281337"},{"key":"51234","doi-asserted-by":"crossref","unstructured":"Wanquet A, Prebet T, Berthon C. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol. 2015; 90(10):859-863.","DOI":"10.1002\/ajh.24099"},{"key":"51235","doi-asserted-by":"crossref","unstructured":"Sallman DA, Barnard J, Al Ali NH. Hypomethylating agent therapy in myelodysplastic syndromes with chromosome 3 abnormalities. Clin Lymphoma Myeloma Leuk. 2020; 20(9):e597-e605.","DOI":"10.1016\/j.clml.2020.03.005"},{"key":"51236","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-232.","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"51237","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30(21):2670-2677.","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"51238","doi-asserted-by":"crossref","unstructured":"Dombret H, Seymour JF, Butrym A. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts. Blood. 2015; 126(3):291-299.","DOI":"10.1182\/blood-2015-01-621664"},{"key":"51239","doi-asserted-by":"crossref","unstructured":"Sitges M, Boluda B, Garrido A. Acute myeloid leukemia with inv(3)(q21.3q26.2)\/t(3;3)(q21.3;q26.2): study of 61 patients treated with intensive protocols. Eur J Haematol. 2020; 105(2):138-147.","DOI":"10.1111\/ejh.13417"},{"key":"51240","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"51241","doi-asserted-by":"crossref","unstructured":"Wei AH, Montesinos P, Ivanov V. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137-2145.","DOI":"10.1182\/blood.2020004856"},{"key":"51242","doi-asserted-by":"crossref","unstructured":"Kadia TM, Reville PK, Borthakur G. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021; 8(8):e552-e561.","DOI":"10.1016\/S2352-3026(21)00192-7"},{"key":"51243","doi-asserted-by":"crossref","unstructured":"Granfeldt Ostgard LS, Medeiros BC, Sengelov H. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015; 33(31):3641-3649.","DOI":"10.1200\/JCO.2014.60.0890"},{"key":"51244","doi-asserted-by":"crossref","unstructured":"Hulegardh E, Nilsson C, Lazarevic V. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015; 90(3):208-214.","DOI":"10.1002\/ajh.23908"},{"key":"51245","doi-asserted-by":"crossref","unstructured":"Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)\/t(3;3). Am J Hematol. 2020; 95(12):E326-E329.","DOI":"10.1002\/ajh.25991"},{"key":"51246","doi-asserted-by":"crossref","unstructured":"Rogers HJ, Hsi ED. Myeloid neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surg Pathol Clin. 2013; 6(4):677-692.","DOI":"10.1016\/j.path.2013.08.007"},{"key":"51247","doi-asserted-by":"crossref","unstructured":"Weisser M, Haferlach C, Haferlach T, Schnittger S. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)\/t(3;3) (q21;q26) positive AML. Leuk Lymphoma. 2007; 48(11):2145-2151.","DOI":"10.1080\/10428190701632848"},{"key":"51248","doi-asserted-by":"crossref","unstructured":"Mohr B, Schetelig J, Schafer-Eckart K. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. Br J Haematol. 2013; 161(2):237-244.","DOI":"10.1111\/bjh.12253"},{"key":"51249","doi-asserted-by":"crossref","unstructured":"Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021; 11(3):64.","DOI":"10.1038\/s41408-021-00457-9"},{"key":"51250","doi-asserted-by":"crossref","unstructured":"Pradhan AK, Mohapatra AD, Nayak KB, Chakraborty S. Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One. 2011; 6(9):e25370.","DOI":"10.1371\/journal.pone.0025370"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282030\/75450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282030\/75936","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11025\/75450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:45Z","timestamp":1794045825000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282030","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}